Stay Ahead of the Game With Insulet (PODD) Q3 Earnings: Wall Street's Insights on Key Metrics

The upcoming report from Insulet (PODD) is expected to reveal quarterly earnings of $0.77 per share, indicating an increase of 8.5% compared to the year-ago period. Analysts forecast revenues of $518.5 million, representing an increase of 19.8% year over year.The consensus EPS estimate for the quarter has undergone a downward revision of 2.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.Bearing this in mind, let's now explore the average estimates of specific Insulet metrics that are commonly monitored and projected by Wall Street analysts.The combined assessment of analysts suggests that 'Revenue- Total Omnipod' will likely reach $514.73 million. The estimate suggests a change of +22% year over year.According to the collective judgment of analysts, 'Revenue- Drug Delivery' should come in at $3.28 million. The estimate points to a change of -69.4% from the year-ago quarter.Analysts expect 'Revenue- International Omnipod' to come in at $123.11 million. The estimate suggests a change of +21.4% year over year.Analysts forecast 'Revenue- U.S. Omnipod' to reach $391.62 million. The estimate indicates a change of +22.2% from the prior-year quarter.View all Key Company Metrics for Insulet here>>>Insulet shares have witnessed a change of +2.5% in the past month, in contrast to the Zacks S&P 500 composite's +0.4% move. With a Zacks Rank #2 (Buy), PODD is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Insulet Corporation (PODD): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks